Increasing generic drug use in medicare part D: The role of government

Journal of the American Geriatrics Society

Volumn 55, Issue 7, 2007, Pages 1106-1109

  Kohl, Senator Herb ^a   Shrank, William H ^b  

^a US Senate   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

AGED; BUDGET; COST CONTROL; DRUG COST; DRUG USE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; MEDICARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

DRUG COSTS; DRUGS, GENERIC; GOVERNMENT REGULATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 34347375751     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01286.x     Document Type: Review

References (40)

1. IMS Health. Available at : Accessed February 5, 2007.
2. Heffler S, Levit K, Smith S et al. Health spending growth up in 1999; faster growth expected in the future. Health Aff (Millwood) 2001 20 : 193 203.
3. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures-2004. Am J Health Syst Pharm 2004 61 : 145 158.
4. Congressional Budget Office. The Budget and Economic Outlook: Fiscal Years 2007 to 2016 [On-line]. Available : Accessed January 30, 2007.
5. McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003 348 : 2635 2645.
6. Shrank WH, Asch SM, Kerr EA et al. The quality of pharmacologic care for adults in the United States. Med Care 2006 44 : 936 945.
7. Higashi T, Shekelle PG, Solomon DH et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004 140 : 714 720.
8. Huskamp HA, Deverka PA, Epstein AM et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003 349 : 2224 2232.
9. Jaeger K. A Message from Kathleen Jaeger: It Pays to Invest in Generics. Pharmacy Times April 2006 [On-line]. Available : Accessed May 7, 2007.
10. Haas JS, Phillips KA, Gerstenberger EP et al. Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000. Ann Intern Med 2005 142 : 891 897.
11. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: Can better care cost less? JAMA 2004 291 : 1850 1856.
12. Cox E, Behm A, Mager D. 2005 Generic Drug Usage Report. Express Scripts, 2006 [On-line]. Available at : Accessed May 7, 2007.
13. Frist WH. Health care in the 21st century. N Engl J Med 2005 352 : 267 272.
14. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2004 summary of findings.
15. Hoadley J, Hargrave E, Cubanski J et al. An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans. The Henry J Kaiser Family Foundation, April 2006.
16. Federman AD, Alexander GC, Shrank WH. Simplifying the medicare prescription drug benefit for physicians and patients. Mayo Clin Proc 2006 81 : 1217 1221.
17. Avorn J. Part "D" for "defective"-the medicare drug-benefit chaos. N Engl J Med 2006 354 : 1339 1341.
18. Shrank WH, Young HN, Ettner SL et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care 2005 11 : 16 22.
19. Shrank WH, Fox SA, Kirk A et al. The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med 2006 21 : 334 339.
20. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003 290 : 953 958.
21. Shrank WH, Hoang T, Ettner SL et al. The implications of choice: Prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med 2006 166 : 332 337.
22. Taira DA, Wong KS, Frech-Tamas F et al. Copayment level and compliance with antihypertensive medication: Analysis and policy implications for managed care. Am J Manag Care 2006 12 : 678 683.
23. Jha AK, Ferris TG, Donelan K et al. How common are electronic health records in the United States? A summary of the evidence. Health Aff (Millwood) 2006 25 : w496 w507.
24. Alexander GC, Casalino LP, Tseng CW et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med 2004 19 : 856 860.
25. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; e-prescribing and the prescription drug program. Final rule. Federal Register. 2005 Nov 7;70(214):67567-95 [On-line]. Available : Accessed January 25, 2007.
26. Kaiser Family Foundation/Harvard School of Public Health. Seniors and the Medicare Prescription Drug Benefit [On-line]. Available: URL : Accessed January 30, 2007.
27. Landon BE, Reschovsky JD, Blumenthal D. Physicians' views of formularies: Implications for medicare drug benefit design. Health Aff (Millwood) 2004 23 : 218 226.
28. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: Lessons for medicare? Health Aff (Millwood) 2003 22 : 149 158.
29. Glassman PA, Tanielian T, Harris K et al. Provider perceptions of pharmacy management: Lessons from the military health system. Med Care 2004 42 : 361 366.
30. Choudhry NK, Avorn J, Schneeweiss S et al. Should post-MI patients receive secondary prevention medications for free? An empirical policy analysis. Health Aff (Millwood) 2007 26 : 186 194.
31. Rosen AB, Hamel MB, Weinstein MC et al. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005 143 : 89 99.
32. O'Malley AJ, Frank RG, Kaddis A et al. Impact of alternative interventions on changes in generic dispensing rates. Health Serv Res 2006 41 : 1876 1894.
33. Fischer MA, Schneeweiss S, Avorn J et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004 351 : 2187 2194.
34. Rosenthal MB, Berndt ER, Donohue JM et al. Promotion of prescription drugs to consumers. N Engl J Med 2002 346 : 498 505.
35. Mott DA, Cline RR. Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002 40 : 662 674.
36. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990 263 : 549 556.
37. Avorn J, Soumerai SB, Everitt DE et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992 327 : 168 173.
38. van Eijk ME, Avorn J, Porsius AJ et al. Reducing prescribing of highly anticholinergic antidepressants for elderly people: Randomised trial of group versus individual academic detailing. BMJ 2001 322 : 654 657.
39. Soumerai SB, Avorn J. Economic and policy analysis of university-based drug "detailing". Med Care 1986 24 : 313 331.
40. Hensley S. Negative advertising: As drug bill soars, some doctors get an 'unsales' pitch. The Wall Street Journal, March 13, 2006, p 1.